Altitude
After the Election, the Fights Move Indoors: ICER, a Courtroom and a New Drug Law for Psilocybin
Policy

After the Election, the Fights Move Indoors: ICER, a Courtroom and a New Drug Law for Psilocybin

The ballots are counted. Now the questions about psychedelic medicine shift to cost reviewers, a Maryland federal court, the FDA's answers to Congress and a bill that would take scheduling away from the DEA.

Nathan Richardson • Nov 7, 2026

A week after the midterms, the next phase of the psilocybin race is playing out somewhere quieter. ICER has opened a cost-effectiveness review of Compass's drug, a trade-secrets suit against Compass is headed for trial, the FDA has answered the House psychedelics caucus, and a retiring congressman wants to rewrite the Controlled Substances Act.

Election week was about who won. The week after it is about who gets to decide what psychedelic medicine costs, who owns the ideas behind it, and which agency gets to say it's legal. None of that happens on a ballot. Four threads are worth following.

ICER is putting a price on psilocybin

The Institute for Clinical and Economic Review, the Boston nonprofit whose reports health insurers lean on when they set coverage rules, announced on Oct. 21 that it will assess Compass Pathways' synthetic psilocybin, COMP360, for treatment-resistant depression. Public comments on the scope of the review close Tuesday, Nov. 10 at 5 p.m. ET. A revised scope follows around Nov. 18, and the evidence goes before ICER's New England advisory council for a public vote in May 2027, likely after an FDA decision.

The field remembers ICER's last psychedelic review. Its 2024 report on Lykos's MDMA-assisted therapy for PTSD raised questions about trial conduct, and the FDA rejected that application a few months later. The Pink Sheet's Cathy Kelly argues this one is unlikely to hit as hard, and the timing helps her case: ICER will be grading a drug the FDA may already have approved.

The precedent that matters more is ICER's 2019 review of esketamine (Spravato), the nasal spray that is today's main branded option for treatment-resistant depression. ICER called it "low value for money" at its list price and estimated that only 16% of eligible patients could be treated before costs crossed its budget threshold. Compass has said it wants COMP360 delivered through the existing network of more than 8,500 sites built for Spravato. How ICER weighs psilocybin against that comparator will shape what insurers are willing to pay.

Compass is headed to court

Terran Biosciences sued Compass in Maryland federal court in 2022, alleging Compass misappropriated trade secrets about combining psilocybin with a drug that blocks the serotonin 2A receptor. On Nov. 2, Law360 reported that the judge had refused to let Compass exit the case, and Psychedelic Alpha's Friday bulletin reports it now has a trial date. The case doesn't touch COMP360's application at the FDA. But it puts Compass in front of a jury during its launch year, against a company whose whole strategy is patenting around branded psychedelics.

The FDA answered Congress

On May 1, House PATH Caucus co-chairs Jack Bergman (R-MI) and Lou Correa (D-CA) led a letter from about 30 members to the FDA, written in the wake of the MDMA rejection. Its first question was how the agency can make Special Protocol Assessments more predictable. An SPA is an agreement on trial design made before a study starts; Lykos had one and was still turned down. Psychedelic Alpha reports that the FDA has now replied and "clarifies limits of SPAs." The letter itself isn't public yet. Both co-chairs won reelection on Tuesday, so the caucus that asked the question will be around to follow up.

A bill to take scheduling away from the DEA

Rep. Steve Cohen (D-TN) introduced the Public Health and Research Reforms in Controlled Substances Act on Oct. 29. Marijuana Moment's Tom Angell reports that it would move scheduling decisions from the DEA to HHS and require psilocybin, LSD, MDMA, DMT and ibogaine to be reevaluated within two years, with new default placements if officials miss the deadline. MAPS, the Drug Policy Alliance, NORML and Students for Sensible Drug Policy have endorsed it. "A thoughtful review of national drug policy is long overdue," Cohen said.

Cohen is retiring, and the bill won't pass in the lame-duck session. Jeffrey Singer at Reason, who supports it with reservations, calls it "a benchmark" for the next Congress. With Democrats now holding both chambers, it's a starting text someone else can pick up.

And the election's aftershocks

Two results reach into this beat. In Iowa, Democrat Rob Sand won the governor's race over a candidate backed by the "Make America Healthy Again" movement. The outgoing governor, Kim Reynolds, vetoed a 2025 bill that would have legalized FDA-approved psilocybin in Iowa automatically, so the next attempt lands on Sand's desk. In Kansas, Sen. Roger Marshall, founder of the congressional MAHA caucus, lost to Democrat Adam Hamilton, per Psychedelic Alpha. MAHA figures, including HHS Secretary Robert F. Kennedy Jr., have been some of psychedelic medicine's loudest Republican backers.

What to watch

  • Mon., Nov. 9: Definium reports third-quarter results after the market closes.
  • Tue., Nov. 10: ICER's comment deadline on the COMP360 review.
  • Around Nov. 17: Compass's two-week window to complete its psilocybin application closes.
  • Fri., Nov. 20: The FDA's ibogaine trial-design comment deadline.

Both psilocybin programs are on our trials tracker, and the companies behind them are on our intelligence hub.

This article is for information only and isn't medical or legal advice. Psilocybin, MDMA and the other compounds named here remain Schedule I under federal law, and none is FDA-approved.

Sources

← Back to Journal